R&D expenses of selected Chinese pharma companies 2021-2022
one to ten 12 of their sales revenue in research and development. That year, Livzon Pharmaceutical Group spent around 1.5 billion yuan on R&D, followed by Changchun High & New Technology Industries Group with 1.1 billion yuan.
In 2021, the Chinese pharmaceutical companies invested between